BLIS M18 ACHIEVES US FDA GRAS "NO OBJECTION" STATUS

BLIS M18 TM Achieves US FDA GRAS "No Objection" status. Blis Technologies Limited announces that their 2nd probiotic strain BLIS M18 TM, has had the issuance of a US Food and Drug Administration 'Letter of No Objection'. This follows the BLIS K12 "Letter of No Objection" in 2016. The Letter of No Objection, more commonly known as GRAS or 'Generally Recognized As Safe', is another recognition of the robust data supporting Blis probiotics. It adds a new level of credibility for BLIS M18 TM and has the potential to open opportunities with larger consumer food and beverage companies in the US, but also is recognised as a relevant and credible safety assessment by other countries and multinational companies. Through the GRAS program, companies may submit their determination supported by research and expert review that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions regarding the notice submitted. For further information please contact: Brian Watson CEO 027 705 9133 About Blis Technologies Ltd Delivering proven health benefits through evidence-based, advanced probiotics Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz. End CA:00333667 For:BLT Type:MKTUPDTE Time:2019-04-24 12:24:55